Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D09QZS
|
|||
| Former ID |
DNCL002598
|
|||
| Drug Name |
Olaratumab
|
|||
| Synonyms |
LY3012207
Click to Show/Hide
|
|||
| Drug Type |
Monoclonal antibody
|
|||
| Indication | Soft tissue sarcoma [ICD-11: 2B57; ICD-9: 171] | Approved | [1] | |
| Non-small-cell lung cancer [ICD-11: 2C25.Y; ICD-9: 183] | Phase 1 | [2] | ||
| Company |
Eli Lilly
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | 2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76. | |||
| REF 2 | ClinicalTrials.gov (NCT02377752) A Study of Olaratumab in Japanese Participants With Advanced Cancer. U.S. National Institutes of Health. | |||
| REF 3 | A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFRalpha) monoclonal antibody, in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2014 Mar;73(3):595-604. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.